- Market Capitalization, $K 375,096
- Shares Outstanding, K 61,897
- Annual Sales, $ 0 K
- Annual Income, $ -91,510 K
- 60-Month Beta 2.56
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 1.48
|Period||Period Low||Period High||Performance|
| || |
+0.60 (+11.26%)since 10/27/23
| || |
-3.23 (-35.46%)since 08/28/23
| || |
-3.56 (-37.71%)since 11/28/22
CMPS earnings call for the period ending September 30, 2023.
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders.
CMPS earnings call for the period ending June 30, 2023.
For biotechs developing psychedelic therapies, good news comes in many forms.
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END
/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...
Wall Street might have the timing wrong, but their hopes aren't misplaced.
/PRNewswire/ - Numinus Wellness Inc. (TSX: NUMI) is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an...
CMPS earnings call for the period ending March 31, 2023.
|Compass Pathways Plc ADR|
|Advisorshares Psychedelics ETF|
|Ark Genomic Revolution ETF|
|Invesco Nasdaq Biotechnology ETF|
|Nasdaq Biotechnology Ishares ETF|
|Putnam Sustainable Future ETF|